EIF2AK4 and diabetic kidney disease: Reinforcing this theory, the use of the halofuginone, a GCN2 activator, prevents extracellular matrix deposition in a murine model of diabetic nephropathy through downregulation of TGF-β signaling and oxidative stress [31].